A type III-A CRISPR-Cas system employs degradosome nucleases to ensure robust immunity.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 30942690.
- Also identified by DOI 10.7554/eLife.45393 and PMC identifier 6447361.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
CRISPR-Cas systems provide sequence-specific immunity against phages and mobile genetic elements using CRISPR-associated nucleases guided by short CRISPR RNAs (crRNAs). Type III systems exhibit a robust immune response that can lead to the extinction of a phage population, a feat coordinated by a multi-subunit effector complex that destroys invading DNA and RNA. Here, we demonstrate that a model type III system in <i>Staphylococcus epidermidis</i> relies upon the activities of two degradosome-associated nucleases, PNPase and RNase J2, to mount a successful defense. Genetic, molecular, and biochemical analyses reveal that PNPase promotes crRNA maturation, and both nucleases are required for efficient clearance of phage-derived nucleic acids. Furthermore, functional assays show that RNase J2 is essential for immunity against diverse mobile genetic elements originating from plasmid and phage. Altogether, our observations reveal the evolution of a critical collaboration between two nucleic acid degrading machines which ensures cell survival when faced with phage attack.
Medical subject headings
- CRISPR-Cas Systems
- Endonucleases
- Endoribonucleases
- Multienzyme Complexes
- Polyribonucleotide Nucleotidyltransferase
- RNA Helicases
- Staphylococcus epidermidis